- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03264976
Role of the Serum Exosomal miRNA in Diabetic Retinopathy (DR)
Prognostic Role of Serum Exosomal miRNA and Its Function in Pathogenesis of Diabetic Retinopathy (DR)
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Förväntat)
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Patients will be chosen according to the inclusion and exclusion standard and written informed consent will be obtained from all participants.
Exit criteria: During the research, for his / her own consideration or at the request of the investigator the patient may withdraw from the trial at any time. For each subject who withdrew from the trial, the investigator must detail the subject's exit date, the reason, and other information in case report form(CRF).
Beskrivning
Inclusion Criteria:
- Type II diabetics,
- Age > 18 years old,
- Have not accepted anti-VEGF therapy,
- Without turbid ocular media or corestenoma that interfere with ophthalmic fundus examination (patients with PDR are excluded).
Exclusion Criteria:
-Patients with any following eye disease in studied eye:
- active infections (i.e., blepharitis, keratitis, scleritis, conjunctivitis, etc.),
- fundus oculi diseases other than DR (i.e., retinal vein occlusion, choroidal neovascularization, retinal detachment, macular hole, vitreous traction in macular region, epiretinal membrane, etc.) ,
uncontrollable glaucoma (intraocular pressure is no less than 25mmHg after anti-glaucoma agents) or after filtering surgery for glaucoma;
-Patients who have accepted any following treatment in studied eyes:
- intraocular injection of corticosteroids (i.e., Triamcinolone) within 3 months, or peribulbar injection of corticosteroids within 1 months,
- vitrectomy surgery,
- anti-VEGF therapy for eyes or other parts of the body (i.e., ranibizumab, bevacizumab, conbercept, aflibercept, pegaptanib sodium, etc),
- any intraocular surgery within 3 months (i.e., cataract surgery, YAG laser capsulectomy, etc),
ocular surgery related with macular region;
-Patients with any following systemic diseases:
- failed blood sugar control within 3 months (Changing treatment from oral antidiabetic therapy into insulin treatment, or start using insulin pump, or doubling the number of injections),
- damaged renal function (Crea is found to be 2 times higher than the upper limit in central laboratory) or abnormal liver function (ALT, AST are found to be 2 times higher than the upper limit in center of the laboratory),
- failed blood pressure control within 3 months (systolic blood pressure is no less than 140 mmHg or diastolic blood pressure is no less than 90 mmHg after hypotensor treatment),
- systemic infection that requires oral, intramuscular or intravenous administration,
- stroke, transient ischemic attack, myocardial infarction or acute congestive heart failure within 6months,
- coagulation dysfunction (thrombin time ≥ normal upper limit of 3 seconds, activation of partial thromboplastin time ≥ normal upper limit of 10 seconds),
- using drugs that may be toxic to the lens, retina or optic nerve during this research (i.e., deferoxamine, chloroquine, hydrogenated chloroquine (chloroquinol), tamoxifen, phenothiazine, or ethambutol, etc.),
diagnosed systemic immune diseases (i.e., mandatory spondylitis, systemic lupus erythematosus, etc.) or any uncontrollable clinical diseases (such as AIDS, malignancy, active hepatitis, severe mental, neurological, cardiovascular, respiratory and other systems diseases, etc.);
-Others:
- pregnant and lactating women,
- those who participated in any drug clinical trials (not including vitamins and minerals) within 3 months,
- those researchers believe that need to be excluded.
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
Group 1
Patients without DR.
Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination.
These information and examinations will be collected at regular intervals: every 12 months until 5 years.
|
Hematological examination includes biochemical examination, routine coagulation test, HbA1c, C reactive protein (CRP);Ophthalmic examination includes the basic situation and clinical diagnosis of eyes, ETDRS visual acuity chart score, intraocular pressure, OCT examination, OCTA examination, fundus photos, Optos wide angle fundus imaging.
|
Group 2
Patients with mild non-proliferative DR (NPDR). Diagnosed according to Diabetic retinopathy PPP - Updated 2016. Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years. |
Hematological examination includes biochemical examination, routine coagulation test, HbA1c, C reactive protein (CRP);Ophthalmic examination includes the basic situation and clinical diagnosis of eyes, ETDRS visual acuity chart score, intraocular pressure, OCT examination, OCTA examination, fundus photos, Optos wide angle fundus imaging.
|
Group 3
Patients with moderate NPDR. Diagnosed according to Diabetic retinopathy PPP - Updated 2016. Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination.These information and examinations will be collected at regular intervals: every 12 months until 5 years. |
Hematological examination includes biochemical examination, routine coagulation test, HbA1c, C reactive protein (CRP);Ophthalmic examination includes the basic situation and clinical diagnosis of eyes, ETDRS visual acuity chart score, intraocular pressure, OCT examination, OCTA examination, fundus photos, Optos wide angle fundus imaging.
|
Group 4
Patients with moderate NPDR. Diagnosed according to Diabetic retinopathy PPP - Updated 2016. Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years. |
Hematological examination includes biochemical examination, routine coagulation test, HbA1c, C reactive protein (CRP);Ophthalmic examination includes the basic situation and clinical diagnosis of eyes, ETDRS visual acuity chart score, intraocular pressure, OCT examination, OCTA examination, fundus photos, Optos wide angle fundus imaging.
|
Group 5
Proliferative DR (PDR). Diagnosed according to Diabetic retinopathy PPP - Updated 2016. Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination.These information and examinations will be collected at regular intervals: every 12 months until 5 years. |
Hematological examination includes biochemical examination, routine coagulation test, HbA1c, C reactive protein (CRP);Ophthalmic examination includes the basic situation and clinical diagnosis of eyes, ETDRS visual acuity chart score, intraocular pressure, OCT examination, OCTA examination, fundus photos, Optos wide angle fundus imaging.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
exosomal miRNAs in serum samples
Tidsram: samples will be collected every 12 months later until 5 years
|
In discovery set, miRNA sequencing of serum exosomes will be performed for each sample.
Data will be analyzed using statistical methods.
Potential miRNAs that show group-differentiation will be selected in combination with information and test results.Based on these selected miRNAs, the same assays will be repeated on all validation set samples to screen out significant miRNA.
|
samples will be collected every 12 months later until 5 years
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Förväntat)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2017-KE-194
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Diabetisk retinopati
-
Association for Innovation and Biomedical Research...Fundação para a Ciência e a TecnologiaAvslutadNPDR - Non Proliferative Diabetic RetinopathyPortugal
-
Ocuphire Pharma, Inc.AvslutadDiabetisk retinopati | Diabetiskt makulaödem | NPDR - Non Proliferative Diabetic Retinopathy | PDR - Proliferativ diabetisk retinopatiFörenta staterna
-
Assiut UniversityOkändom Vitreomacular Interface Abnormalities in Diabetic Retinopathy
-
Association for Innovation and Biomedical Research...European Vision Institute Clinical Research NetworkAktiv, inte rekryterandeDiabetes mellitus, typ 2 | Näthinnesjukdom | NPDR - Non Proliferative Diabetic RetinopathyFrankrike, Italien, Portugal
-
The Eye Center and The Eye Foundation for Research...King Khalid University HospitalAvslutadHydroxychloroquine Toxic RetinopathySaudiarabien
-
Dr. S.S. Michel ClinicAvslutadSickle Cell Retinopathy
-
Fondation Ophtalmologique Adolphe de RothschildAvslutadMEK Inhibitor-Associated Serous RetinopathyFrankrike
-
Fayoum UniversityCairo UniversityHar inte rekryterat ännuSGLT2i Kideny Protection Against Contrast in Diabetic Kidney
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RekryteringSicklecellanemi | Sickle Cell SC-sjukdom | Sickle Cell-SS-sjukdom | Sickle Cell RetinopathyNederländerna
Kliniska prövningar på hematological examination, ophthalmic examination
-
University of EdinburghNHS LothianAvslutadCauda Equina syndrom | Funktionell neurologisk störningStorbritannien
-
University Hospital, ToulouseOkändExtrakorporeal membransyresättningskomplikationFrankrike
-
Centre Hospitalier Universitaire de la RéunionRekryteringNeurokognitivt underskottÅterförening
-
Istanbul UniversityAvslutad
-
Carilion ClinicDigitally Enhanced Screening ApplicationsIndragenKognitiv förändring
-
University Hospital Center of MartiniqueAvslutadAlzheimers sjukdom | Äldre patienter | Kognitiv störningFrankrike
-
Azienda Ospedaliera Universitaria Integrata VeronaOkändKognitiv försämring | Fibromyalgi | Smärta, kronisk | Fibromyalgi syndrom | Nedsättning
-
Centro Hospitalar do PortoOkändPostoperativa komplikationer | Neurokognitiva störningar | Postoperativ periodPortugal
-
Centre Francois BaclesseAvslutad
-
Centre Hospitalier Universitaire, AmiensIndragenAlzheimers sjukdom | KognitionsstörningFrankrike